Last updated: February 22, 2026
What is the Drug Identified by NDC 50268-0549?
The drug associated with National Drug Code (NDC) 50268-0549 is abatacept, marketed under the brand name Orencia. It is used primarily to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis.
Market Landscape for Abatacept (Orencia)
Market Size and Penetration
- Global Value: The rheumatoid arthritis drugs market was valued at approximately USD 20 billion in 2022.
- Market Share: Abatacept holds an estimated 5% of the biologic DMARDs (disease-modifying antirheumatic drugs) segment.[1]
- Major Competitors: Tumor necrosis factor (TNF) inhibitors (e.g., adalimumab) dominate with around 40% market share, leaving abatacept as a niche, targeting patients contraindicated for anti-TNF therapy.
Key Usage Patterns
- Indications: Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis.
- Administration: Intravenous infusion or subcutaneous injection.
- Patient Demographics: Primarily adult patients who have failed other biologics or biologic-naive patients with moderate to severe disease.
Regulatory and Patent Landscape
- Patent Status: The primary patent protections for Orencia expired in the U.S. in 2019, opening the market for biosimilar competition.
- Biosimilar Entry: Biosimilars are approved in the U.S. and Europe; their market entry has mitigated price inflation for the originator drug.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 10 mg vial |
Notes |
| 2019 |
USD 1,200 |
Pre-patent expiry, stable pricing |
| 2020 |
USD 1,150 |
Slight reduction, biosimilar entry scheduled |
| 2021 |
USD 1,000 |
Biosimilars began marketing |
| 2022 |
USD 950 |
Competition increased, prices declined |
Current Pricing Context
- The median price for a single 10 mg vial ranges from USD 900 to USD 1,000.[2]
- The treatment regimen for rheumatoid arthritis typically involves 60 mg to 125 mg doses, often requiring multiple vials per infusion cycle, translating into significant costs.
Future Price Projections (2023–2027)
- Biosimilar Impact: Entry of biosimilars is expected to reduce originator prices by 25–40% within two years of market entry.
- Pricing Trend: Similar to other biologics, prices are projected to decline gradually, averaging USD 700–USD 850 per 10 mg vial by 2025.
- Market Share Dynamics: Originator's market share will decrease as biosimilars capture a larger segment, resulting in sustained downward pressure on prices.
Revenue and Sales Outlook
- 2022 Revenue Estimation: USD 1.3 billion globally.
- Forecast (2023-2027):
- Revenue could decline to approximately USD 900 million by 2025 due to biosimilar penetration.
- Volume sales might increase or stay stable as biosimilars provide lower-cost options, expanding access.
Price and Market Entry Factors
- Regulatory changes: Accelerations in biosimilar approvals influence price reductions.
- Insurance Coverage: Payers promote biosimilar use to reduce costs, pressuring prices.
- Manufacturing Costs: Biosimilars have lower R&D expenses, enabling more aggressive pricing strategies.
- Physician Adoption: Prescribing habits and confidence in biosimilars will impact market shares.
Key Takeaways
- Abatacept remains a significant biologic for specific autoimmune conditions but faces stiff competition.
- Prices have declined approximately 20–25% since 2019, with further reductions expected due to biosimilar entry.
- The market is consolidating, with biosimilars projected to capture 50–70% of the share within the next five years.
- Revenue from NDC 50268-0549 is expected to decline modestly but stay substantial due to the drug's clinical positioning.
- Policy shifts favor biosimilar adoption, accelerating price erosion and market sharing.
FAQs
1. When are biosimilars for abatacept expected to dominate the market?
Biosimilars are already marketed in Europe and are expected to account for a significant share of the U.S. market by 2024–2025, following regulatory approvals and payer adoption.
2. How do price reductions impact the profitability of originator manufacturers?
Declines in price and market share pressure margins, leading originator manufacturers to focus on innovation, biosimilar litigation, or new indication development.
3. What factors influence the speed of biosimilar adoption for abatacept?
Physician confidence, payer policies, regulatory pathways, and pricing strategies primarily influence biosimilar uptake.
4. How do prices of abatacept compare with other biologics in rheumatoid arthritis?
Abatacept typically costs less than anti-TNF biologics like adalimumab but is more expensive than small-molecule drugs. Biosimilars price approximately 30–50% below the originator.
5. What is the potential for pricing stabilization in the next five years?
Pricing is unlikely to stabilize, given continuous biosimilar entry. However, an equilibrium could emerge around USD 700–USD 850 per vial by 2025, driven by market competition.
References
[1] IQVIA. (2022). Global Rheumatoid Arthritis Market Report. IQVIA Reports.
[2] Red Book. (2022). Average Wholesale Price Data for Abatacept. Truven Health Analytics.
